JP5378998B2 - 炎症性メディエーターの放出を減弱させるための方法及びそれにおいて有用なペプチド - Google Patents

炎症性メディエーターの放出を減弱させるための方法及びそれにおいて有用なペプチド Download PDF

Info

Publication number: JP5378998B2
Authority: JP; Japan
Prior art keywords: peptide; amino acid; inflammatory; group; cells
Prior art date: 2006-07-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP2009522007A

Other languages

English (en)

Japanese (ja)

Other versions

JP2009544737A (ja

JP2009544737A5 (da

Inventor

パリク，インドウ

Original Assignee

バイオマーク・フアーマシユーテイカルズ・リミテツド

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-07-26

Filing date

2007-07-26

Publication date

2013-12-25

2007-07-26 Application filed by バイオマーク・フアーマシユーテイカルズ・リミテツド filed Critical バイオマーク・フアーマシユーテイカルズ・リミテツド

2009-12-17 Publication of JP2009544737A publication Critical patent/JP2009544737A/ja

2010-10-07 Publication of JP2009544737A5 publication Critical patent/JP2009544737A5/ja

2013-12-25 Application granted granted Critical

2013-12-25 Publication of JP5378998B2 publication Critical patent/JP5378998B2/ja

Status Expired - Fee Related legal-status Critical Current

2027-07-26 Anticipated expiration legal-status Critical

Links

230000002757 inflammatory effect Effects 0.000 title claims abstract description 159
108090000765 processed proteins & peptides Proteins 0.000 title claims description 1020
238000000034 method Methods 0.000 title abstract description 81
102000004196 processed proteins & peptides Human genes 0.000 title description 120
239000008187 granular material Substances 0.000 claims abstract description 84
210000004969 inflammatory cell Anatomy 0.000 claims abstract description 78
230000002401 inhibitory effect Effects 0.000 claims abstract description 35
210000000440 neutrophil Anatomy 0.000 claims description 85
206010061218 Inflammation Diseases 0.000 claims description 69
230000004054 inflammatory process Effects 0.000 claims description 69
108090000235 Myeloperoxidases Proteins 0.000 claims description 67
102000003896 Myeloperoxidases Human genes 0.000 claims description 67
-1 β-D-glucuronidase Proteins 0.000 claims description 59
108090000623 proteins and genes Proteins 0.000 claims description 49
108010092408 Eosinophil Peroxidase Proteins 0.000 claims description 42
102000044708 Eosinophil peroxidases Human genes 0.000 claims description 42
210000003979 eosinophil Anatomy 0.000 claims description 42
102000004169 proteins and genes Human genes 0.000 claims description 42
235000018102 proteins Nutrition 0.000 claims description 41
210000000265 leukocyte Anatomy 0.000 claims description 39
150000001875 compounds Chemical class 0.000 claims description 37
102000016943 Muramidase Human genes 0.000 claims description 34
229960000274 lysozyme Drugs 0.000 claims description 34
235000010335 lysozyme Nutrition 0.000 claims description 34
108010014251 Muramidase Proteins 0.000 claims description 33
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 33
239000004325 lysozyme Substances 0.000 claims description 33
239000008194 pharmaceutical composition Substances 0.000 claims description 29
201000010099 disease Diseases 0.000 claims description 26
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
210000003714 granulocyte Anatomy 0.000 claims description 24
102000001398 Granzyme Human genes 0.000 claims description 20
108060005986 Granzyme Proteins 0.000 claims description 20
210000001616 monocyte Anatomy 0.000 claims description 18
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 16
102000035195 Peptidases Human genes 0.000 claims description 14
108091005804 Peptidases Proteins 0.000 claims description 14
208000023504 respiratory system disease Diseases 0.000 claims description 14
210000002540 macrophage Anatomy 0.000 claims description 13
210000003651 basophil Anatomy 0.000 claims description 12
208000017520 skin disease Diseases 0.000 claims description 11
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 10
201000003883 Cystic fibrosis Diseases 0.000 claims description 10
208000006673 asthma Diseases 0.000 claims description 10
206010006458 Bronchitis chronic Diseases 0.000 claims description 9
101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims description 9
239000004365 Protease Substances 0.000 claims description 9
206010006451 bronchitis Diseases 0.000 claims description 9
239000005482 chemotactic factor Substances 0.000 claims description 9
208000007451 chronic bronchitis Diseases 0.000 claims description 9
102000004127 Cytokines Human genes 0.000 claims description 8
108090000695 Cytokines Proteins 0.000 claims description 8
208000002193 Pain Diseases 0.000 claims description 8
230000000844 anti-bacterial effect Effects 0.000 claims description 8
229960001340 histamine Drugs 0.000 claims description 8
230000036407 pain Effects 0.000 claims description 8
208000011580 syndromic disease Diseases 0.000 claims description 8
102000016387 Pancreatic elastase Human genes 0.000 claims description 7
108010067372 Pancreatic elastase Proteins 0.000 claims description 7
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 claims description 6
102000003908 Cathepsin D Human genes 0.000 claims description 6
108090000258 Cathepsin D Proteins 0.000 claims description 6
102000004173 Cathepsin G Human genes 0.000 claims description 6
108090000617 Cathepsin G Proteins 0.000 claims description 6
102000029816 Collagenase Human genes 0.000 claims description 6
108060005980 Collagenase Proteins 0.000 claims description 6
102000013382 Gelatinases Human genes 0.000 claims description 6
108010026132 Gelatinases Proteins 0.000 claims description 6
108010063045 Lactoferrin Proteins 0.000 claims description 6
102000010445 Lactoferrin Human genes 0.000 claims description 6
102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 claims description 6
108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 claims description 6
229960002424 collagenase Drugs 0.000 claims description 6
CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 6
229940078795 lactoferrin Drugs 0.000 claims description 6
235000021242 lactoferrin Nutrition 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims description 5
102000004225 Cathepsin B Human genes 0.000 claims description 5
108090000712 Cathepsin B Proteins 0.000 claims description 5
102000000541 Defensins Human genes 0.000 claims description 5
108010002069 Defensins Proteins 0.000 claims description 5
108010008211 N-Formylmethionine Leucyl-Phenylalanine Proteins 0.000 claims description 5
102000015439 Phospholipases Human genes 0.000 claims description 5
108010064785 Phospholipases Proteins 0.000 claims description 5
108010001014 Plasminogen Activators Proteins 0.000 claims description 5
102000001938 Plasminogen Activators Human genes 0.000 claims description 5
102000019199 alpha-Mannosidase Human genes 0.000 claims description 5
108010012864 alpha-Mannosidase Proteins 0.000 claims description 5
239000003242 anti bacterial agent Substances 0.000 claims description 5
230000003110 anti-inflammatory effect Effects 0.000 claims description 5
230000000295 complement effect Effects 0.000 claims description 5
102000006834 complement receptors Human genes 0.000 claims description 5
108010047295 complement receptors Proteins 0.000 claims description 5
229940127126 plasminogen activator Drugs 0.000 claims description 5
235000019833 protease Nutrition 0.000 claims description 5
235000019419 proteases Nutrition 0.000 claims description 5
102100039160 Amiloride-sensitive amine oxidase [copper-containing] Human genes 0.000 claims description 4
108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 claims description 4
102000002297 Laminin Receptors Human genes 0.000 claims description 4
108010000851 Laminin Receptors Proteins 0.000 claims description 4
208000012658 Skin autoimmune disease Diseases 0.000 claims description 4
102000011409 Transcobalamins Human genes 0.000 claims description 4
108010023603 Transcobalamins Proteins 0.000 claims description 4
239000012190 activator Substances 0.000 claims description 4
230000002141 anti-parasite Effects 0.000 claims description 4
230000000840 anti-viral effect Effects 0.000 claims description 4
229940088710 antibiotic agent Drugs 0.000 claims description 4
239000003096 antiparasitic agent Chemical class 0.000 claims description 4
229940094517 chondroitin 4-sulfate Drugs 0.000 claims description 4
KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims description 4
PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 claims description 3
239000002955 immunomodulating agent Substances 0.000 claims description 3
229940121354 immunomodulator Drugs 0.000 claims description 3
102000018832 Cytochromes Human genes 0.000 claims description 2
108010052832 Cytochromes Proteins 0.000 claims description 2
230000001225 therapeutic effect Effects 0.000 claims description 2
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 claims 1
208000028774 intestinal disease Diseases 0.000 claims 1
238000011321 prophylaxis Methods 0.000 claims 1
230000028327 secretion Effects 0.000 abstract description 88
108010025061 MARCKS-related peptide Proteins 0.000 abstract description 87
230000008569 process Effects 0.000 abstract description 21
230000007246 mechanism Effects 0.000 abstract description 16
230000003834 intracellular effect Effects 0.000 abstract description 15
230000003248 secreting effect Effects 0.000 abstract description 11
102000007079 Peptide Fragments Human genes 0.000 abstract description 9
230000001413 cellular effect Effects 0.000 abstract description 7
108010033276 Peptide Fragments Proteins 0.000 abstract description 6
230000007728 intracellular signaling mechanism Effects 0.000 abstract description 2
230000000144 pharmacologic effect Effects 0.000 abstract 1
125000003275 alpha amino acid group Chemical group 0.000 description 287
235000001014 amino acid Nutrition 0.000 description 211
229940024606 amino acid Drugs 0.000 description 183
210000004027 cell Anatomy 0.000 description 170
150000001413 amino acids Chemical class 0.000 description 165
108010063737 Myristoylated Alanine-Rich C Kinase Substrate Proteins 0.000 description 131
102000015695 Myristoylated Alanine-Rich C Kinase Substrate Human genes 0.000 description 124
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 90
239000012634 fragment Substances 0.000 description 77
PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 72
PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 70
230000000694 effects Effects 0.000 description 65
238000006467 substitution reaction Methods 0.000 description 58
241000282414 Homo sapiens Species 0.000 description 56
239000000203 mixture Substances 0.000 description 47
150000001408 amides Chemical group 0.000 description 38
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 37
210000004899 c-terminal region Anatomy 0.000 description 37
210000004379 membrane Anatomy 0.000 description 36
239000012528 membrane Substances 0.000 description 36
102000003923 Protein Kinase C Human genes 0.000 description 35
108090000315 Protein Kinase C Proteins 0.000 description 35
238000012217 deletion Methods 0.000 description 31
230000037430 deletion Effects 0.000 description 31
102000015728 Mucins Human genes 0.000 description 29
108010063954 Mucins Proteins 0.000 description 29
230000004913 activation Effects 0.000 description 29
101001046426 Homo sapiens cGMP-dependent protein kinase 1 Proteins 0.000 description 28
102100022422 cGMP-dependent protein kinase 1 Human genes 0.000 description 28
239000000126 substance Substances 0.000 description 28
210000001519 tissue Anatomy 0.000 description 28
OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 24
101710176384 Peptide 1 Proteins 0.000 description 24
230000002829 reductive effect Effects 0.000 description 24
238000011282 treatment Methods 0.000 description 24
125000001433 C-terminal amino-acid group Chemical group 0.000 description 23
230000028023 exocytosis Effects 0.000 description 23
YUFCOOWNNHGGOD-UMMCILCDSA-N 8-bromo-3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1Br YUFCOOWNNHGGOD-UMMCILCDSA-N 0.000 description 22
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 22
238000007792 addition Methods 0.000 description 21
230000026731 phosphorylation Effects 0.000 description 21
238000006366 phosphorylation reaction Methods 0.000 description 21
125000002843 carboxylic acid group Chemical group 0.000 description 20
101000741929 Caenorhabditis elegans Serine/threonine-protein phosphatase 2A catalytic subunit Proteins 0.000 description 19
210000000170 cell membrane Anatomy 0.000 description 19
230000004936 stimulating effect Effects 0.000 description 19
125000003277 amino group Chemical group 0.000 description 18
229910021529 ammonia Inorganic materials 0.000 description 18
238000003556 assay Methods 0.000 description 18
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 18
210000000805 cytoplasm Anatomy 0.000 description 18
LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
102000000583 SNARE Proteins Human genes 0.000 description 17
108010041948 SNARE Proteins Proteins 0.000 description 17
150000007933 aliphatic carboxylic acids Chemical group 0.000 description 17
230000001419 dependent effect Effects 0.000 description 17
230000030609 dephosphorylation Effects 0.000 description 17
238000006209 dephosphorylation reaction Methods 0.000 description 17
239000000523 sample Substances 0.000 description 17
230000027455 binding Effects 0.000 description 16
230000000638 stimulation Effects 0.000 description 16
150000002148 esters Chemical group 0.000 description 15
230000005764 inhibitory process Effects 0.000 description 15
210000000822 natural killer cell Anatomy 0.000 description 15
239000000243 solution Substances 0.000 description 15
210000004369 blood Anatomy 0.000 description 14
239000008280 blood Substances 0.000 description 14
230000004044 response Effects 0.000 description 14
229920006395 saturated elastomer Polymers 0.000 description 14
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 13
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 13
230000006378 damage Effects 0.000 description 13
108010026901 peptide 106 Proteins 0.000 description 13
125000000217 alkyl group Chemical group 0.000 description 12
125000000539 amino acid group Chemical group 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 12
230000001472 cytotoxic effect Effects 0.000 description 12
125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 12
239000000137 peptide hydrolase inhibitor Substances 0.000 description 12
238000012360 testing method Methods 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
241001465754 Metazoa Species 0.000 description 11
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
230000001086 cytosolic effect Effects 0.000 description 11
239000002158 endotoxin Substances 0.000 description 11
239000003112 inhibitor Substances 0.000 description 11
210000003097 mucus Anatomy 0.000 description 11
239000003826 tablet Substances 0.000 description 11
102000004190 Enzymes Human genes 0.000 description 10
108090000790 Enzymes Proteins 0.000 description 10
239000004471 Glycine Substances 0.000 description 10
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
206010020751 Hypersensitivity Diseases 0.000 description 10
208000026935 allergic disease Diseases 0.000 description 10
150000001412 amines Chemical class 0.000 description 10
229940088598 enzyme Drugs 0.000 description 10
238000009472 formulation Methods 0.000 description 10
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 10
229920006008 lipopolysaccharide Polymers 0.000 description 10
230000001105 regulatory effect Effects 0.000 description 10
102000007469 Actins Human genes 0.000 description 9
108010085238 Actins Proteins 0.000 description 9
108020004414 DNA Proteins 0.000 description 9
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
230000007815 allergy Effects 0.000 description 9
230000007423 decrease Effects 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
239000000546 pharmaceutical excipient Substances 0.000 description 9
230000002685 pulmonary effect Effects 0.000 description 9
210000000130 stem cell Anatomy 0.000 description 9
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 8
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 8
239000004472 Lysine Substances 0.000 description 8
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
241000124008 Mammalia Species 0.000 description 8
125000001931 aliphatic group Chemical group 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
210000001124 body fluid Anatomy 0.000 description 8
239000010839 body fluid Substances 0.000 description 8
230000006870 function Effects 0.000 description 8
230000001404 mediated effect Effects 0.000 description 8
QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 8
VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 8
230000009467 reduction Effects 0.000 description 8
239000000758 substrate Substances 0.000 description 8
239000006228 supernatant Substances 0.000 description 8
TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical group CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
241000282472 Canis lupus familiaris Species 0.000 description 7
208000011231 Crohn disease Diseases 0.000 description 7
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
241000282412 Homo Species 0.000 description 7
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 7
102000003505 Myosin Human genes 0.000 description 7
108060008487 Myosin Proteins 0.000 description 7
239000002253 acid Substances 0.000 description 7
239000004480 active ingredient Substances 0.000 description 7
230000010933 acylation Effects 0.000 description 7
238000005917 acylation reaction Methods 0.000 description 7
206010003246 arthritis Diseases 0.000 description 7
230000000903 blocking effect Effects 0.000 description 7
150000001732 carboxylic acid derivatives Chemical class 0.000 description 7
239000002299 complementary DNA Substances 0.000 description 7
239000003937 drug carrier Substances 0.000 description 7
235000019441 ethanol Nutrition 0.000 description 7
210000000224 granular leucocyte Anatomy 0.000 description 7
238000001114 immunoprecipitation Methods 0.000 description 7
238000011534 incubation Methods 0.000 description 7
210000004897 n-terminal region Anatomy 0.000 description 7
101800002712 p27 Proteins 0.000 description 7
239000000843 powder Substances 0.000 description 7
239000002904 solvent Substances 0.000 description 7
230000000451 tissue damage Effects 0.000 description 7
231100000827 tissue damage Toxicity 0.000 description 7
VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 6
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 6
241000282465 Canis Species 0.000 description 6
WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 6
206010009900 Colitis ulcerative Diseases 0.000 description 6
201000004624 Dermatitis Diseases 0.000 description 6
108010050456 Eosinophil-Derived Neurotoxin Proteins 0.000 description 6
102000013888 Eosinophil-Derived Neurotoxin Human genes 0.000 description 6
239000012981 Hank's balanced salt solution Substances 0.000 description 6
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
108091034117 Oligonucleotide Proteins 0.000 description 6
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 6
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 6
201000004681 Psoriasis Diseases 0.000 description 6
108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
201000006704 Ulcerative Colitis Diseases 0.000 description 6
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 6
125000002252 acyl group Chemical group 0.000 description 6
239000000443 aerosol Substances 0.000 description 6
235000004279 alanine Nutrition 0.000 description 6
230000002238 attenuated effect Effects 0.000 description 6
231100000433 cytotoxic Toxicity 0.000 description 6
230000004069 differentiation Effects 0.000 description 6
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 6
235000013922 glutamic acid Nutrition 0.000 description 6
239000004220 glutamic acid Substances 0.000 description 6
235000004554 glutamine Nutrition 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
208000014674 injury Diseases 0.000 description 6
208000032839 leukemia Diseases 0.000 description 6
210000004698 lymphocyte Anatomy 0.000 description 6
238000005259 measurement Methods 0.000 description 6
230000005012 migration Effects 0.000 description 6
238000013508 migration Methods 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
238000007911 parenteral administration Methods 0.000 description 6
230000008506 pathogenesis Effects 0.000 description 6
230000037361 pathway Effects 0.000 description 6
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 6
229920001223 polyethylene glycol Polymers 0.000 description 6
210000004739 secretory vesicle Anatomy 0.000 description 6
239000000021 stimulant Substances 0.000 description 6
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
238000011200 topical administration Methods 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
208000002874 Acne Vulgaris Diseases 0.000 description 5
239000004475 Arginine Substances 0.000 description 5
208000023275 Autoimmune disease Diseases 0.000 description 5
241000283086 Equidae Species 0.000 description 5
241000282326 Felis catus Species 0.000 description 5
208000022559 Inflammatory bowel disease Diseases 0.000 description 5
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 5
102000016611 Proteoglycans Human genes 0.000 description 5
108010067787 Proteoglycans Proteins 0.000 description 5
239000012980 RPMI-1640 medium Substances 0.000 description 5
102000006382 Ribonucleases Human genes 0.000 description 5
108010083644 Ribonucleases Proteins 0.000 description 5
241001303601 Rosacea Species 0.000 description 5
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
102100030552 Synaptosomal-associated protein 25 Human genes 0.000 description 5
229920004890 Triton X-100 Polymers 0.000 description 5
239000013504 Triton X-100 Substances 0.000 description 5
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
208000027418 Wounds and injury Diseases 0.000 description 5
206010000496 acne Diseases 0.000 description 5
230000000692 anti-sense effect Effects 0.000 description 5
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
208000010668 atopic eczema Diseases 0.000 description 5
239000000872 buffer Substances 0.000 description 5
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
229940079593 drug Drugs 0.000 description 5
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
239000001257 hydrogen Substances 0.000 description 5
229910052739 hydrogen Inorganic materials 0.000 description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
230000036039 immunity Effects 0.000 description 5
208000015181 infectious disease Diseases 0.000 description 5
230000002132 lysosomal effect Effects 0.000 description 5
239000002609 medium Substances 0.000 description 5
239000002245 particle Substances 0.000 description 5
229930192851 perforin Natural products 0.000 description 5
210000005259 peripheral blood Anatomy 0.000 description 5
239000011886 peripheral blood Substances 0.000 description 5
230000035699 permeability Effects 0.000 description 5
206010039073 rheumatoid arthritis Diseases 0.000 description 5
201000004700 rosacea Diseases 0.000 description 5
230000018448 secretion by cell Effects 0.000 description 5
239000000725 suspension Substances 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
DAZBILQQVFBVPE-XKKUQSFHSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-4-amino-2-[[2-[[(2r)-2-[[(2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexan Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O)CCC1 DAZBILQQVFBVPE-XKKUQSFHSA-N 0.000 description 4
JPOKAKNGULMYHZ-UILVTTEASA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-3-(4-hydroxyp Chemical compound C([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 JPOKAKNGULMYHZ-UILVTTEASA-N 0.000 description 4
MUSGYEMSJUFFHT-UWABRSFTSA-N 2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cn(C)c3ccccc23)NC(=O)[C@@H](NC1=O)C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)C(N)=O MUSGYEMSJUFFHT-UWABRSFTSA-N 0.000 description 4
208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 4
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
102000010032 Calcium-Independent Phospholipases A2 Human genes 0.000 description 4
108010077241 Calcium-Independent Phospholipases A2 Proteins 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
102000057955 Eosinophil Cationic Human genes 0.000 description 4
101710191360 Eosinophil cationic protein Proteins 0.000 description 4
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
108091000080 Phosphotransferase Proteins 0.000 description 4
102000001253 Protein Kinase Human genes 0.000 description 4
102000015799 Qa-SNARE Proteins Human genes 0.000 description 4
108010010469 Qa-SNARE Proteins Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 4
108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 4
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
239000004473 Threonine Substances 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
235000009582 asparagine Nutrition 0.000 description 4
229960001230 asparagine Drugs 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
239000013592 cell lysate Substances 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
235000010980 cellulose Nutrition 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
238000012512 characterization method Methods 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
230000001276 controlling effect Effects 0.000 description 4
210000004395 cytoplasmic granule Anatomy 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 4
239000003862 glucocorticoid Substances 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
210000003630 histaminocyte Anatomy 0.000 description 4
VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 4
208000002551 irritable bowel syndrome Diseases 0.000 description 4
238000002955 isolation Methods 0.000 description 4
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
229960000310 isoleucine Drugs 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
238000004949 mass spectrometry Methods 0.000 description 4
244000005700 microbiome Species 0.000 description 4
239000002773 nucleotide Substances 0.000 description 4
125000003729 nucleotide group Chemical group 0.000 description 4
108010011990 peptide 74 Proteins 0.000 description 4
238000010647 peptide synthesis reaction Methods 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
102000020233 phosphotransferase Human genes 0.000 description 4
108010005636 polypeptide C Proteins 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
239000000047 product Substances 0.000 description 4
108060006633 protein kinase Proteins 0.000 description 4
239000007787 solid Substances 0.000 description 4
229940037128 systemic glucocorticoids Drugs 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
238000012546 transfer Methods 0.000 description 4
238000012384 transportation and delivery Methods 0.000 description 4
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
235000002374 tyrosine Nutrition 0.000 description 4
239000004474 valine Substances 0.000 description 4
125000004400 (C1-C12) alkyl group Chemical group 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 3
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 3
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
208000035143 Bacterial infection Diseases 0.000 description 3
102100025287 Cytochrome b Human genes 0.000 description 3
108010075028 Cytochromes b Proteins 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
241000233866 Fungi Species 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
206010018364 Glomerulonephritis Diseases 0.000 description 3
102100030826 Hemoglobin subunit epsilon Human genes 0.000 description 3
101001083591 Homo sapiens Hemoglobin subunit epsilon Proteins 0.000 description 3
102000004157 Hydrolases Human genes 0.000 description 3
108090000604 Hydrolases Proteins 0.000 description 3
108010002350 Interleukin-2 Proteins 0.000 description 3
102000000588 Interleukin-2 Human genes 0.000 description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
235000021360 Myristic acid Nutrition 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
229930182555 Penicillin Natural products 0.000 description 3
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
102000012479 Serine Proteases Human genes 0.000 description 3
108010022999 Serine Proteases Proteins 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
239000000853 adhesive Substances 0.000 description 3
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 3
201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
239000000556 agonist Substances 0.000 description 3
230000029936 alkylation Effects 0.000 description 3
238000005804 alkylation reaction Methods 0.000 description 3
238000010640 amide synthesis reaction Methods 0.000 description 3
239000000074 antisense oligonucleotide Substances 0.000 description 3
238000012230 antisense oligonucleotides Methods 0.000 description 3
238000013459 approach Methods 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
208000022362 bacterial infectious disease Diseases 0.000 description 3
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
LSUTUUOITDQYNO-UHFFFAOYSA-N calphostin C Chemical compound C=12C3=C4C(CC(C)OC(=O)C=5C=CC=CC=5)=C(OC)C(O)=C(C(C=C5OC)=O)C4=C5C=1C(OC)=CC(=O)C2=C(O)C(OC)=C3CC(C)OC(=O)OC1=CC=C(O)C=C1 LSUTUUOITDQYNO-UHFFFAOYSA-N 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
239000002775 capsule Substances 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
210000000845 cartilage Anatomy 0.000 description 3
125000002091 cationic group Chemical group 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
208000037976 chronic inflammation Diseases 0.000 description 3
JKNIRLKHOOMGOJ-UHFFFAOYSA-N cladochrome D Natural products COC1=C(CC(C)OC(=O)Oc2ccc(O)cc2)c3c4C(=C(OC)C(=O)c5c(O)cc(OC)c(c45)c6c(OC)cc(O)c(C1=O)c36)CC(C)OC(=O)c7ccc(O)cc7 JKNIRLKHOOMGOJ-UHFFFAOYSA-N 0.000 description 3
SRJYZPCBWDVSGO-UHFFFAOYSA-N cladochrome E Natural products COC1=CC(O)=C(C(C(OC)=C(CC(C)OC(=O)OC=2C=CC(O)=CC=2)C2=3)=O)C2=C1C1=C(OC)C=C(O)C(C(C=2OC)=O)=C1C=3C=2CC(C)OC(=O)C1=CC=CC=C1 SRJYZPCBWDVSGO-UHFFFAOYSA-N 0.000 description 3
230000008602 contraction Effects 0.000 description 3
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
229940112141 dry powder inhaler Drugs 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
230000002327 eosinophilic effect Effects 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
239000012530 fluid Substances 0.000 description 3
235000013355 food flavoring agent Nutrition 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
229910052736 halogen Inorganic materials 0.000 description 3
150000002367 halogens Chemical group 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000004968 inflammatory condition Effects 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
239000008101 lactose Substances 0.000 description 3
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 3
108010052968 leupeptin Proteins 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000012669 liquid formulation Substances 0.000 description 3
239000000314 lubricant Substances 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
230000034217 membrane fusion Effects 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
CSHFHJNMIMPJST-HOTGVXAUSA-N methyl (2s)-2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoate Chemical compound NCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)OC)CC1=CC=CC=C1 CSHFHJNMIMPJST-HOTGVXAUSA-N 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
206010063344 microscopic polyangiitis Diseases 0.000 description 3
229940049954 penicillin Drugs 0.000 description 3
108010091212 pepstatin Proteins 0.000 description 3
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 3
108010009779 peptide 32 Proteins 0.000 description 3
YYCZLGUOLIWZAW-GVETXGJZSA-N peptide 75 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)C(C)C)C1=CC=CC=C1 YYCZLGUOLIWZAW-GVETXGJZSA-N 0.000 description 3
239000002644 phorbol ester Substances 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
230000000770 proinflammatory effect Effects 0.000 description 3
229960004063 propylene glycol Drugs 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
210000002345 respiratory system Anatomy 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
150000003335 secondary amines Chemical class 0.000 description 3
230000011218 segmentation Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
241000894007 species Species 0.000 description 3
230000001954 sterilising effect Effects 0.000 description 3
238000004659 sterilization and disinfection Methods 0.000 description 3
229960005322 streptomycin Drugs 0.000 description 3
229960004793 sucrose Drugs 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
239000002562 thickening agent Substances 0.000 description 3
DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
NBIIXXVUZAFLBC-HOSYLAQJSA-K trioxido(oxo)-$l^{5}-phosphane Chemical compound [O-][32P]([O-])([O-])=O NBIIXXVUZAFLBC-HOSYLAQJSA-K 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
SBHCLVQMTBWHCD-METXMMQOSA-N (2e,4e,6e,8e,10e)-icosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C(O)=O SBHCLVQMTBWHCD-METXMMQOSA-N 0.000 description 2
UDTXUDHDIVNHCL-AENUQYPBSA-N (2s)-2-[[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-4-methylpe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O UDTXUDHDIVNHCL-AENUQYPBSA-N 0.000 description 2
BNIFSVVAHBLNTN-XKKUQSFHSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-4-amino-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexan Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O)CCC1 BNIFSVVAHBLNTN-XKKUQSFHSA-N 0.000 description 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
PVVTWNMXEHROIA-UHFFFAOYSA-N 2-(3-hydroxypropyl)-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(CCCO)=NC(=O)C2=C1 PVVTWNMXEHROIA-UHFFFAOYSA-N 0.000 description 2
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical group COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical class C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
UXTIAFYTYOEQHV-UHFFFAOYSA-N 4-(4-amino-3-methoxyphenyl)-2-methoxyaniline;hydron;dichloride Chemical compound [Cl-].[Cl-].C1=C([NH3+])C(OC)=CC(C=2C=C(OC)C([NH3+])=CC=2)=C1 UXTIAFYTYOEQHV-UHFFFAOYSA-N 0.000 description 2
OYHQOLUKZRVURQ-UHFFFAOYSA-N 9,12-Octadecadienoic Acid Chemical compound CCCCCC=CCC=CCCCCCCCC(O)=O OYHQOLUKZRVURQ-UHFFFAOYSA-N 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
102000013563 Acid Phosphatase Human genes 0.000 description 2
108010051457 Acid Phosphatase Proteins 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
102100033312 Alpha-2-macroglobulin Human genes 0.000 description 2
229920000945 Amylopectin Polymers 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
244000187129 Bacopa monnieria Species 0.000 description 2
235000015418 Bacopa monnieria Nutrition 0.000 description 2
235000021357 Behenic acid Nutrition 0.000 description 2
102100036849 C-C motif chemokine 24 Human genes 0.000 description 2
102100021935 C-C motif chemokine 26 Human genes 0.000 description 2
102000017926 CHRM2 Human genes 0.000 description 2
101001110283 Canis lupus familiaris Ras-related C3 botulinum toxin substrate 1 Proteins 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
108010083647 Chemokine CCL24 Proteins 0.000 description 2
108010083698 Chemokine CCL26 Proteins 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
108010069514 Cyclic Peptides Proteins 0.000 description 2
102000001189 Cyclic Peptides Human genes 0.000 description 2
101710112752 Cytotoxin Proteins 0.000 description 2
GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
206010014561 Emphysema Diseases 0.000 description 2
102100023688 Eotaxin Human genes 0.000 description 2
101710139422 Eotaxin Proteins 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
102000053187 Glucuronidase Human genes 0.000 description 2
108010060309 Glucuronidase Proteins 0.000 description 2
108010016306 Glycylpeptide N-tetradecanoyltransferase Proteins 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
101001099460 Homo sapiens Myeloperoxidase Proteins 0.000 description 2
101001059479 Homo sapiens Myristoylated alanine-rich C-kinase substrate Proteins 0.000 description 2
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
108010002616 Interleukin-5 Proteins 0.000 description 2
108090001007 Interleukin-8 Proteins 0.000 description 2
102000004890 Interleukin-8 Human genes 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
150000008575 L-amino acids Chemical class 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
108010007622 LDL Lipoproteins Proteins 0.000 description 2
102000007330 LDL Lipoproteins Human genes 0.000 description 2
208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
235000021353 Lignoceric acid Nutrition 0.000 description 2
CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 2
102000005741 Metalloproteases Human genes 0.000 description 2
108010006035 Metalloproteases Proteins 0.000 description 2
HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
235000021314 Palmitic acid Nutrition 0.000 description 2
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
108010003541 Platelet Activating Factor Proteins 0.000 description 2
108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 2
108010005730 R-SNARE Proteins Proteins 0.000 description 2
206010063837 Reperfusion injury Diseases 0.000 description 2
229940122055 Serine protease inhibitor Drugs 0.000 description 2
101710102218 Serine protease inhibitor Proteins 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
102000002215 Synaptobrevin Human genes 0.000 description 2
102000013265 Syntaxin 1 Human genes 0.000 description 2
108010090618 Syntaxin 1 Proteins 0.000 description 2
HXWJFEZDFPRLBG-UHFFFAOYSA-N Timnodonic acid Natural products CCCC=CC=CCC=CCC=CCC=CCCCC(O)=O HXWJFEZDFPRLBG-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
108010009583 Transforming Growth Factors Proteins 0.000 description 2
102000009618 Transforming Growth Factors Human genes 0.000 description 2
UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 description 2
241000700605 Viruses Species 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
239000000205 acacia gum Substances 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000010398 acute inflammatory response Effects 0.000 description 2
230000001464 adherent effect Effects 0.000 description 2
230000001070 adhesive effect Effects 0.000 description 2
210000001552 airway epithelial cell Anatomy 0.000 description 2
OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 2
230000009435 amidation Effects 0.000 description 2
238000007112 amidation reaction Methods 0.000 description 2
125000003368 amide group Chemical group 0.000 description 2
230000006229 amino acid addition Effects 0.000 description 2
238000011861 anti-inflammatory therapy Methods 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
238000000376 autoradiography Methods 0.000 description 2
229940116226 behenic acid Drugs 0.000 description 2
230000008901 benefit Effects 0.000 description 2
GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000011575 calcium Substances 0.000 description 2
244000309466 calf Species 0.000 description 2
150000001721 carbon Chemical group 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
239000002975 chemoattractant Substances 0.000 description 2
208000037893 chronic inflammatory disorder Diseases 0.000 description 2
SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
239000003086 colorant Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 description 2
231100000599 cytotoxic agent Toxicity 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
239000002619 cytotoxin Substances 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000006735 deficit Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000018044 dehydration Effects 0.000 description 2
238000006297 dehydration reaction Methods 0.000 description 2
238000003795 desorption Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
235000013681 dietary sucrose Nutrition 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
MBMBGCFOFBJSGT-SFGLVEFQSA-N docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C\C\C=C\C\C=C\C\C=C\C\C=C\C\C=C\CCC(O)=O MBMBGCFOFBJSGT-SFGLVEFQSA-N 0.000 description 2
MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
KFEVDPWXEVUUMW-UHFFFAOYSA-N docosanoic acid Natural products CCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 KFEVDPWXEVUUMW-UHFFFAOYSA-N 0.000 description 2
LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000000835 fiber Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
LQJBNNIYVWPHFW-VAWYXSNFSA-N gadelaidic acid Chemical compound CCCCCCCCCC\C=C\CCCCCCCC(O)=O LQJBNNIYVWPHFW-VAWYXSNFSA-N 0.000 description 2
VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
210000002175 goblet cell Anatomy 0.000 description 2
230000012010 growth Effects 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
102000047241 human MARCKS Human genes 0.000 description 2
102000051251 human MPO Human genes 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
230000028993 immune response Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
239000012678 infectious agent Substances 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
230000004941 influx Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
108010056777 interleukin-2 (59-72) Proteins 0.000 description 2
210000004020 intracellular membrane Anatomy 0.000 description 2
230000006662 intracellular pathway Effects 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
IUPKBWSKNCAQJQ-JYYYXURSSA-N kisspeptin 234 Chemical compound C([C@H](NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(C)=O)C)C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=CC=C1 IUPKBWSKNCAQJQ-JYYYXURSSA-N 0.000 description 2
238000002372 labelling Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
230000002101 lytic effect Effects 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
210000003632 microfilament Anatomy 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
238000002156 mixing Methods 0.000 description 2
125000002950 monocyclic group Chemical group 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
SECPZKHBENQXJG-BQYQJAHWSA-N palmitelaidic acid Chemical compound CCCCCC\C=C\CCCCCCCC(O)=O SECPZKHBENQXJG-BQYQJAHWSA-N 0.000 description 2
238000005192 partition Methods 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 2
108010012038 peptide 78 Proteins 0.000 description 2
229940125863 peptide 78 Drugs 0.000 description 2
239000012071 phase Substances 0.000 description 2
238000003752 polymerase chain reaction Methods 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
150000003077 polyols Chemical class 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
229910000160 potassium phosphate Inorganic materials 0.000 description 2
235000011009 potassium phosphates Nutrition 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
150000003141 primary amines Chemical class 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
230000009822 protein phosphorylation Effects 0.000 description 2
238000011002 quantification Methods 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
201000006845 reticulosarcoma Diseases 0.000 description 2
208000029922 reticulum cell sarcoma Diseases 0.000 description 2
235000019204 saccharin Nutrition 0.000 description 2
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
229940081974 saccharin Drugs 0.000 description 2
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
230000007017 scission Effects 0.000 description 2
230000000580 secretagogue effect Effects 0.000 description 2
230000009962 secretion pathway Effects 0.000 description 2
239000003001 serine protease inhibitor Substances 0.000 description 2
230000011664 signaling Effects 0.000 description 2
230000007727 signaling mechanism Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
239000011343 solid material Substances 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
238000000527 sonication Methods 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008107 starch Substances 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
229940124530 sulfonamide Drugs 0.000 description 2
125000000565 sulfonamide group Chemical group 0.000 description 2
150000003456 sulfonamides Chemical class 0.000 description 2
230000001629 suppression Effects 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
210000001179 synovial fluid Anatomy 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
230000008685 targeting Effects 0.000 description 2
QZZGJDVWLFXDLK-UHFFFAOYSA-N tetracosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(O)=O QZZGJDVWLFXDLK-UHFFFAOYSA-N 0.000 description 2
UWHZIFQPPBDJPM-BQYQJAHWSA-N trans-vaccenic acid Chemical compound CCCCCC\C=C\CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-BQYQJAHWSA-N 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
230000035899 viability Effects 0.000 description 2
239000001993 wax Substances 0.000 description 2
DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 2
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
IIWXYWWVCBRBCJ-UHFFFAOYSA-N 12-aminododecan-1-ol Chemical compound NCCCCCCCCCCCCO IIWXYWWVCBRBCJ-UHFFFAOYSA-N 0.000 description 1
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical compound OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 1
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
BLFRQYKZFKYQLO-UHFFFAOYSA-N 4-aminobutan-1-ol Chemical compound NCCCCO BLFRQYKZFKYQLO-UHFFFAOYSA-N 0.000 description 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
PHEDXBVPIONUQT-LQLWEASQSA-N 63597-44-4 Chemical compound C([C@@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-LQLWEASQSA-N 0.000 description 1
206010027654 Allergic conditions Diseases 0.000 description 1
208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
208000031295 Animal disease Diseases 0.000 description 1
102000009133 Arylsulfatases Human genes 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
238000009010 Bradford assay Methods 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
102000001902 CC Chemokines Human genes 0.000 description 1
108010040471 CC Chemokines Proteins 0.000 description 1
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000000584 Calmodulin Human genes 0.000 description 1
108010041952 Calmodulin Proteins 0.000 description 1
102000005367 Carboxypeptidases Human genes 0.000 description 1
108010006303 Carboxypeptidases Proteins 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
239000005973 Carvone Substances 0.000 description 1
102000005600 Cathepsins Human genes 0.000 description 1
108010084457 Cathepsins Proteins 0.000 description 1
108010055166 Chemokine CCL5 Proteins 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
101150012960 Chrm2 gene Proteins 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
102100024539 Chymase Human genes 0.000 description 1
108090000227 Chymases Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000001187 Collagen Type III Human genes 0.000 description 1
108010069502 Collagen Type III Proteins 0.000 description 1
108010078015 Complement C3b Proteins 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
229920002261 Corn starch Chemical class 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
201000004315 EAST syndrome Diseases 0.000 description 1
241000257465 Echinoidea Species 0.000 description 1
102000016942 Elastin Human genes 0.000 description 1
108010014258 Elastin Proteins 0.000 description 1
241000792859 Enema Species 0.000 description 1
208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
208000007530 Essential hypertension Diseases 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
208000001640 Fibromyalgia Diseases 0.000 description 1
241000192125 Firmicutes Species 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
102100028085 Glycylpeptide N-tetradecanoyltransferase 1 Human genes 0.000 description 1
208000009329 Graft vs Host Disease Diseases 0.000 description 1
208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
229920002971 Heparan sulfate Polymers 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101001081567 Homo sapiens Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
101000828633 Homo sapiens Synaptobrevin homolog YKT6 Proteins 0.000 description 1
101000671638 Homo sapiens Vesicle transport protein USE1 Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
102100027636 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 1
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
102100020881 Interleukin-1 alpha Human genes 0.000 description 1
108010082786 Interleukin-1alpha Proteins 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
102000004889 Interleukin-6 Human genes 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
102000007547 Laminin Human genes 0.000 description 1
108010085895 Laminin Proteins 0.000 description 1
108010028275 Leukocyte Elastase Proteins 0.000 description 1
102000016799 Leukocyte elastase Human genes 0.000 description 1
239000000232 Lipid Bilayer Substances 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241000192041 Micrococcus Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010049567 Miller Fisher syndrome Diseases 0.000 description 1
101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
102000007474 Multiprotein Complexes Human genes 0.000 description 1
108010085220 Multiprotein Complexes Proteins 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
102000006386 Myelin Proteins Human genes 0.000 description 1
108010083674 Myelin Proteins Proteins 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
102000004722 NADPH Oxidases Human genes 0.000 description 1
108010002998 NADPH Oxidases Proteins 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
102000006447 Phospholipases A2 Human genes 0.000 description 1
108010058864 Phospholipases A2 Proteins 0.000 description 1
108010065084 Phosphorylase a Proteins 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
229920002367 Polyisobutene Polymers 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
208000035977 Rare disease Diseases 0.000 description 1
102000042087 SNAP-25 family Human genes 0.000 description 1
108091080044 SNAP-25 family Proteins 0.000 description 1
108010077895 Sarcosine Proteins 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
206010040844 Skin exfoliation Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
108700017375 Specific Granule Deficiency Proteins 0.000 description 1
101000693530 Staphylococcus aureus Staphylokinase Proteins 0.000 description 1
102100023512 Synaptobrevin homolog YKT6 Human genes 0.000 description 1
208000004732 Systemic Vasculitis Diseases 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000001400 Tryptase Human genes 0.000 description 1
108060005989 Tryptase Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
102100040106 Vesicle transport protein USE1 Human genes 0.000 description 1
102000003786 Vesicle-associated membrane protein 2 Human genes 0.000 description 1
108090000169 Vesicle-associated membrane protein 2 Proteins 0.000 description 1
102100033220 Xanthine oxidase Human genes 0.000 description 1
108010093894 Xanthine oxidase Proteins 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
NBIIXXVUZAFLBC-HOSYLAQJSA-N ac1l2fov Chemical compound O[32P](O)(O)=O NBIIXXVUZAFLBC-HOSYLAQJSA-N 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
238000003916 acid precipitation Methods 0.000 description 1
ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
208000038016 acute inflammation Diseases 0.000 description 1
230000006022 acute inflammation Effects 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
208000037883 airway inflammation Diseases 0.000 description 1
210000005091 airway smooth muscle Anatomy 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
125000005233 alkylalcohol group Chemical group 0.000 description 1
230000009285 allergic inflammation Effects 0.000 description 1
230000003281 allosteric effect Effects 0.000 description 1
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
125000001124 arachidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
230000005784 autoimmunity Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000003796 beauty Effects 0.000 description 1
125000003910 behenoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000000424 bronchial epithelial cell Anatomy 0.000 description 1
201000009267 bronchiectasis Diseases 0.000 description 1
230000007885 bronchoconstriction Effects 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000000378 calcium silicate Substances 0.000 description 1
229910052918 calcium silicate Inorganic materials 0.000 description 1
229960003340 calcium silicate Drugs 0.000 description 1
235000012241 calcium silicate Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 1
150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
239000012707 chemical precursor Substances 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
229940096384 chicken egg white lysozyme Drugs 0.000 description 1
201000001352 cholecystitis Diseases 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
239000011651 chromium Substances 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
230000012085 chronic inflammatory response Effects 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000011382 collagen catabolic process Effects 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
239000000306 component Substances 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000008120 corn starch Chemical class 0.000 description 1
238000012937 correction Methods 0.000 description 1
230000004940 costimulation Effects 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
230000010013 cytotoxic mechanism Effects 0.000 description 1
125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000035618 desquamation Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
150000001991 dicarboxylic acids Chemical class 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
208000010643 digestive system disease Diseases 0.000 description 1
SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000011363 dried mixture Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
229920002549 elastin Polymers 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000007184 endocrine pathway Effects 0.000 description 1
230000002121 endocytic effect Effects 0.000 description 1
230000022770 endosome transport Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
DLFVBJFMPXGRIB-UHFFFAOYSA-M ethanimidate Chemical compound CC([O-])=N DLFVBJFMPXGRIB-UHFFFAOYSA-M 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
150000002190 fatty acyls Chemical group 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
150000003948 formamides Chemical class 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000007499 fusion processing Methods 0.000 description 1
208000018685 gastrointestinal system disease Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
150000002309 glutamines Chemical class 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000000227 grinding Methods 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
238000005658 halogenation reaction Methods 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000000409 histolytic effect Effects 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
150000002431 hydrogen Chemical group 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
150000001261 hydroxy acids Chemical class 0.000 description 1
125000002768 hydroxyalkyl group Chemical group 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
239000005550 inflammation mediator Substances 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000037041 intracellular level Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
208000012947 ischemia reperfusion injury Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
210000001503 joint Anatomy 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
229920001427 mPEG Polymers 0.000 description 1
230000031852 maintenance of location in cell Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229940071648 metered dose inhaler Drugs 0.000 description 1
229940063557 methacrylate Drugs 0.000 description 1
229940095102 methyl benzoate Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
108091005601 modified peptides Proteins 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
210000003003 monocyte-macrophage precursor cell Anatomy 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
230000000921 morphogenic effect Effects 0.000 description 1
230000003843 mucus production Effects 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000005012 myelin Anatomy 0.000 description 1
210000001167 myeloblast Anatomy 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
230000002956 necrotizing effect Effects 0.000 description 1
210000001640 nerve ending Anatomy 0.000 description 1
210000005044 neurofilament Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000003957 neurotransmitter release Effects 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
231100000065 noncytotoxic Toxicity 0.000 description 1
230000002020 noncytotoxic effect Effects 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000036542 oxidative stress Effects 0.000 description 1
108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
244000045947 parasite Species 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000008447 perception Effects 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
210000000680 phagosome Anatomy 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
150000004633 phorbol derivatives Chemical class 0.000 description 1
238000003616 phosphatase activity assay Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229940012957 plasmin Drugs 0.000 description 1
210000002706 plastid Anatomy 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
229910000105 potassium hydride Inorganic materials 0.000 description 1
229920001592 potato starch Chemical class 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
150000003138 primary alcohols Chemical class 0.000 description 1
150000005375 primary alkyl halides Chemical class 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
210000004206 promonocyte Anatomy 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000000730 protein immunoprecipitation Methods 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000004850 protein–protein interaction Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
239000003642 reactive oxygen metabolite Substances 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000019254 respiratory burst Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
238000003118 sandwich ELISA Methods 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
229940043230 sarcosine Drugs 0.000 description 1
102000014452 scavenger receptors Human genes 0.000 description 1
108010078070 scavenger receptors Proteins 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000003352 sequestering agent Substances 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
239000013464 silicone adhesive Substances 0.000 description 1
238000004088 simulation Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000002884 skin cream Substances 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
UIICPZFWHBJNIG-UHFFFAOYSA-N sodium;2-methoxyethanolate Chemical compound [Na+].COCC[O-] UIICPZFWHBJNIG-UHFFFAOYSA-N 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
208000000162 specific granule deficiency Diseases 0.000 description 1
239000007921 spray Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000011232 storage material Substances 0.000 description 1
239000008362 succinate buffer Substances 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
108060007951 sulfatase Proteins 0.000 description 1
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
210000002504 synaptic vesicle Anatomy 0.000 description 1
210000003568 synaptosome Anatomy 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
210000004876 tela submucosa Anatomy 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
238000011191 terminal modification Methods 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
230000007838 tissue remodeling Effects 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
210000003956 transport vesicle Anatomy 0.000 description 1
230000008733 trauma Effects 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
125000001527 trienoyl group Chemical group 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
238000003211 trypan blue cell staining Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
210000003934 vacuole Anatomy 0.000 description 1
210000001186 vagus nerve Anatomy 0.000 description 1
ATCJTYORYKLVIA-SRXJVYAUSA-N vamp regimen Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ATCJTYORYKLVIA-SRXJVYAUSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000008728 vascular permeability Effects 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
239000013598 vector Substances 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
102000028728 vitamin binding proteins Human genes 0.000 description 1
108091009357 vitamin binding proteins Proteins 0.000 description 1
238000001262 western blot Methods 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940045860 white wax Drugs 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Zoology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Otolaryngology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Transplantation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

JP2009522007A 2006-07-26 2007-07-26 炎症性メディエーターの放出を減弱させるための方法及びそれにおいて有用なペプチド Expired - Fee Related JP5378998B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US83323906P	2006-07-26	2006-07-26
US60/833,239		2006-07-26
PCT/US2007/074514 WO2008014414A2 (en)	2006-07-26	2007-07-26	Methods for attenuating release of inflammatory mediators and peptides useful therein

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2013145459A Division JP5819889B2 (ja)	2006-07-26	2013-07-11	炎症性メディエーターの放出を減弱させるための方法及びそれにおいて有用なペプチド

Publications (3)

Publication Number	Publication Date
JP2009544737A JP2009544737A (ja)	2009-12-17
JP2009544737A5 JP2009544737A5 (da)	2010-10-07
JP5378998B2 true JP5378998B2 (ja)	2013-12-25

Family

ID=38982357

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2009522007A Expired - Fee Related JP5378998B2 (ja)	2006-07-26	2007-07-26	炎症性メディエーターの放出を減弱させるための方法及びそれにおいて有用なペプチド
JP2013145459A Expired - Fee Related JP5819889B2 (ja)	2006-07-26	2013-07-11	炎症性メディエーターの放出を減弱させるための方法及びそれにおいて有用なペプチド

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2013145459A Expired - Fee Related JP5819889B2 (ja)	2006-07-26	2013-07-11	炎症性メディエーターの放出を減弱させるための方法及びそれにおいて有用なペプチド

Country Status (21)

Country	Link
US (6)	US8999915B2 (da)
EP (2)	EP2053915B1 (da)
JP (2)	JP5378998B2 (da)
KR (1)	KR101599894B1 (da)
CN (2)	CN103990111B (da)
AU (1)	AU2007279193B2 (da)
BR (1)	BRPI0714953A2 (da)
CA (2)	CA2658949C (da)
DK (2)	DK2722052T3 (da)
ES (2)	ES2725599T3 (da)
HR (1)	HRP20140587T1 (da)
IL (1)	IL196667A (da)
MX (1)	MX2009000975A (da)
NO (1)	NO20090304L (da)
PL (2)	PL2722052T3 (da)
PT (1)	PT2053915E (da)
RU (1)	RU2423376C2 (da)
SG (2)	SG173411A1 (da)
SI (1)	SI2053915T1 (da)
WO (1)	WO2008014414A2 (da)
ZA (1)	ZA200900550B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ577196A (en)	2005-01-20	2011-06-30	Biomarck Pharmaceuticals Ltd	Mucin hypersecretion inhibitors based on the structure of MANS and methods of use
CN103990111B (zh)	2006-07-26	2016-08-31	拜欧马克医药有限公司	减少炎症介质释放的方法和可用于该方法的肽
EP3309556B1 (en) *	2009-06-25	2020-04-08	Prometheus Biosciences, Inc.	Methods for diagnosing irritable bowel syndrome
WO2011060349A1 (en) *	2009-11-13	2011-05-19	North Carolina State University	Methods of modulating mesenchymal stem cells
SG10201708125PA (en)	2013-04-05	2017-11-29	Biomarck Pharmaceuticals Ltd	Inhibitors of metastasis
WO2015013669A1 (en)	2013-07-26	2015-01-29	The Regents Of The University Of California	Mps peptides and use thereof
US10314889B2 (en)	2013-12-20	2019-06-11	The Regents Of The University Of California	Suppression of allergic lung inflammation and hyperreactivity
KR102181548B1 (ko) *	2019-02-20	2020-11-20	한국외국어대학교 연구산학협력단	염증성 질환 또는 자가면역성 질환의 예방 또는 치료 활성을 갖는 펩타이드 및 이의 용도
KR20210151945A (ko)	2019-04-12	2021-12-14	립타이드 바이오사이언스, 인코포레이티드	대식세포 활성을 조정하기 위한 방법
JP2022537318A (ja)	2019-06-17	2022-08-25	バイオマルクファーマシューティカルズリミテッド	ぶどう膜炎の処置におけるペプチド及びその使用の方法
EP4475866A4 (en) *	2022-02-07	2026-02-25	Park Strategic Ventures Llc	Peptides and their methods of use in the treatment of eye disorders
CA3250538A1 (en) *	2022-04-25	2023-11-02	Park Strategic Ventures Llc	PEPTIDES AND RELATED METHODS OF USE IN THE TREATMENT OF SKIN DISEASES
CN116375796A (zh) *	2022-11-24	2023-07-04	华南农业大学	一种来源于珍珠贝的抗炎肽及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS61265341A (ja) *	1985-05-17	1986-11-25	Kawasaki Heavy Ind Ltd	Ｖ型エンジンのシリンダ−ブロツク構造
US4873346A (en) *	1985-09-20	1989-10-10	The Upjohn Company	Substituted benzothiazoles, benzimidazoles, and benzoxazoles
US4753945A (en) *	1986-02-19	1988-06-28	Eye Research Institute Of Retina Foundation	Stimulation of tear secretion with phosphodiesterase inhibitors
US4966848A (en) *	1988-02-08	1990-10-30	The General Hospital Corporation	Isolation, purification, characterization, cloning and sequencing of N α-acetyltransferase
CA2003316A1 (en)	1988-11-18	1990-05-18	John F. Oram	Hdl-binding proteins
US5223421A (en) *	1989-10-25	1993-06-29	The General Hospital Corporation	Identification of methionine Nα-acetyltransferase
CA2093125C (en)	1990-10-02	2003-12-16	Warner-Lambert Company	Angiotensin ii antagonists
US5292498A (en) *	1991-06-19	1994-03-08	The University Of North Carolina At Chapel Hill	Method of treating lung disease with uridine triphosphates
EP0593580A4 (en)	1991-06-20	1995-12-06	Us Health	Sequences characteristic of human gene transcription product
US5858784A (en) *	1991-12-17	1999-01-12	The Regents Of The University Of California	Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0551200A1 (en)	1992-01-07	1993-07-14	National University Of Singapore	Protein phosphatase inhibitors for use in therapy
US5298506A (en) *	1992-05-08	1994-03-29	Brigham And Women's Hospital	Use of guanylate cyclase inhibitors in the treatment of shock
US5861502A (en) *	1992-11-09	1999-01-19	Thomas Jefferson University	Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
US5512269A (en) *	1993-06-09	1996-04-30	Burroughs Wellcome, Co.	Method of treating retained pulmonary secretions
US5849719A (en) *	1993-08-26	1998-12-15	The Regents Of The University Of California	Method for treating allergic lung disease
US5858981A (en) *	1993-09-30	1999-01-12	University Of Pennsylvania	Method of inhibiting phagocytosis
US5436243A (en) *	1993-11-17	1995-07-25	Research Triangle Institute Duke University	Aminoanthraquinone derivatives to combat multidrug resistance
JPH10502333A (ja)	1994-04-07	1998-03-03	プロティーンニックスカンパニー	バソアクティブ・インテスティナル・ポリペプチド
US5985822A (en)	1994-12-09	1999-11-16	The Scripps Research Institute	Inhibition of glial cell proliferation with N-CAM homophilic peptides
US6713605B1 (en) *	1996-04-10	2004-03-30	Kansas State University Research Foundation	Synthetic peptides that inhibit leukocyte superoxide anion production and/or attract leukocytes
US5688489A (en) *	1995-09-15	1997-11-18	Resolution Pharmaceuticals, Inc.	Non-receptor mediated imaging agents
GB9620390D0 (en) *	1996-09-30	1996-11-13	Eisai London Res Lab Ltd	Substances and their uses
DE19716713A1 (de)	1997-04-21	1998-10-22	Paz Arzneimittelentwicklung	Arzneimittel, enthaltend Ibuprofenthioester als Hemmer der Nf-kappaB abhängigen Bildung von Mediatoren von Entzündung und Schmerz
US7544772B2 (en) *	2001-06-26	2009-06-09	Biomarck Pharmaceuticals, Ltd.	Methods for regulating inflammatory mediators and peptides useful therein
US8501911B2 (en) *	1999-02-24	2013-08-06	Biomarck Pharmaceuticals, Ltd	Methods of reducing inflammation and mucus hypersecretion
EP1538162B1 (en) *	1999-02-24	2012-04-11	North Carolina State University	Compositions for altering mucus secretion
US6245320B1 (en) *	1999-09-01	2001-06-12	University Of Maryland	Inhibition of mucin release from airway goblet cells by polycationic peptides
WO2001020998A1 (en)	1999-09-24	2001-03-29	Linden Technologies, Inc.	Drug discovery using gene expression profiling
CA2326970C (en) *	1999-12-03	2004-11-23	Pfizer Products Inc.	Acetylene derivatives as anti-inflammatory/analgesic agents
US7265088B1 (en)	2000-02-24	2007-09-04	North Carolina State University	Method and compositions for altering mucus secretion
US7919469B2 (en) *	2000-02-24	2011-04-05	North Carolina State University	Methods and compositions for altering mucus secretion
PT1411967E (pt) *	2001-06-26	2011-09-30	Univ North Carolina State	Péptido bloqueador que atua sobre a secreção de células inflamatórias
JP2004049133A (ja)	2002-07-22	2004-02-19	Kumamoto Technology & Industry Foundation	Ｎ−ミリストイルトランスフェラーゼ活性の測定方法
US7598080B2 (en) *	2004-08-20	2009-10-06	Carl Deirmengian	Diagnostic assay for source of inflammation
US7408030B2 (en) *	2005-01-13	2008-08-05	North Carolina State University	Purification of immunoglobulins using affinity chromatography and peptide ligands
NZ577196A (en) *	2005-01-20	2011-06-30	Biomarck Pharmaceuticals Ltd	Mucin hypersecretion inhibitors based on the structure of MANS and methods of use
CN103990111B (zh)	2006-07-26	2016-08-31	拜欧马克医药有限公司	减少炎症介质释放的方法和可用于该方法的肽

2007
- 2007-07-26 CN CN201410224653.8A patent/CN103990111B/zh not_active Expired - Fee Related
- 2007-07-26 JP JP2009522007A patent/JP5378998B2/ja not_active Expired - Fee Related
- 2007-07-26 KR KR1020097004065A patent/KR101599894B1/ko not_active Expired - Fee Related
- 2007-07-26 AU AU2007279193A patent/AU2007279193B2/en not_active Ceased
- 2007-07-26 EP EP07840538.8A patent/EP2053915B1/en active Active
- 2007-07-26 DK DK14151431.5T patent/DK2722052T3/da active
- 2007-07-26 SG SG2011053303A patent/SG173411A1/en unknown
- 2007-07-26 PT PT78405388T patent/PT2053915E/pt unknown
- 2007-07-26 BR BRPI0714953-0A2A patent/BRPI0714953A2/pt not_active Application Discontinuation
- 2007-07-26 MX MX2009000975A patent/MX2009000975A/es active IP Right Grant
- 2007-07-26 ZA ZA200900550A patent/ZA200900550B/xx unknown
- 2007-07-26 EP EP14151431.5A patent/EP2722052B1/en active Active
- 2007-07-26 WO PCT/US2007/074514 patent/WO2008014414A2/en not_active Ceased
- 2007-07-26 ES ES14151431T patent/ES2725599T3/es active Active
- 2007-07-26 PL PL14151431T patent/PL2722052T3/pl unknown
- 2007-07-26 ES ES07840538.8T patent/ES2488092T3/es active Active
- 2007-07-26 HR HRP20140587TT patent/HRP20140587T1/hr unknown
- 2007-07-26 CA CA2658949A patent/CA2658949C/en active Active
- 2007-07-26 DK DK07840538.8T patent/DK2053915T3/da active
- 2007-07-26 CA CA2842219A patent/CA2842219C/en active Active
- 2007-07-26 SI SI200731481T patent/SI2053915T1/sl unknown
- 2007-07-26 PL PL07840538T patent/PL2053915T3/pl unknown
- 2007-07-26 SG SG10201500418QA patent/SG10201500418QA/en unknown
- 2007-07-26 RU RU2009106673/04A patent/RU2423376C2/ru active
- 2007-07-26 CN CN200780035710.6A patent/CN101516190B/zh not_active Expired - Fee Related
2009
- 2009-01-20 NO NO20090304A patent/NO20090304L/no not_active Application Discontinuation
- 2009-01-22 IL IL196667A patent/IL196667A/en active IP Right Grant
- 2009-01-26 US US12/359,892 patent/US8999915B2/en active Active
2013
- 2013-07-11 JP JP2013145459A patent/JP5819889B2/ja not_active Expired - Fee Related
2015
- 2015-03-04 US US14/638,208 patent/US9827287B2/en not_active Expired - Fee Related
2017
- 2017-10-20 US US15/789,442 patent/US20180036367A1/en not_active Abandoned
2018
- 2018-12-28 US US16/235,880 patent/US20200138898A1/en not_active Abandoned
2021
- 2021-05-04 US US17/307,471 patent/US20210260154A1/en not_active Abandoned
2023
- 2023-04-05 US US18/296,275 patent/US20230293629A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US8999915B2 (en)	2015-04-07
IL196667A (en)	2017-04-30
RU2423376C2 (ru)	2011-07-10
CA2842219A1 (en)	2008-01-31
PT2053915E (pt)	2014-08-25
US20160030509A1 (en)	2016-02-04
ES2725599T3 (es)	2019-09-25
EP2722052A1 (en)	2014-04-23
CN103990111A (zh)	2014-08-20
JP2009544737A (ja)	2009-12-17
PL2053915T3 (pl)	2014-12-31
SG173411A1 (en)	2011-08-29
BRPI0714953A2 (pt)	2013-07-16
SG10201500418QA (en)	2015-03-30
US20180036367A1 (en)	2018-02-08
CN101516190B (zh)	2014-06-11
HK1125793A1 (en)	2009-08-21
EP2053915A2 (en)	2009-05-06
IL196667A0 (en)	2011-08-01
HRP20140587T1 (hr)	2014-11-21
KR101599894B1 (ko)	2016-03-04
WO2008014414A3 (en)	2008-09-25
AU2007279193B2 (en)	2011-12-01
NO20090304L (no)	2009-04-21
DK2722052T3 (da)	2019-04-29
EP2053915B1 (en)	2014-06-11
MX2009000975A (es)	2009-04-07
JP5819889B2 (ja)	2015-11-24
ES2488092T3 (es)	2014-08-26
DK2053915T3 (da)	2014-06-30
SI2053915T1 (sl)	2014-10-30
EP2053915A4 (en)	2011-06-08
WO2008014414A2 (en)	2008-01-31
HK1201190A1 (en)	2015-08-28
CA2842219C (en)	2017-07-11
AU2007279193A1 (en)	2008-01-31
CN101516190A (zh)	2009-08-26
CA2658949A1 (en)	2008-01-31
US20210260154A1 (en)	2021-08-26
US20230293629A1 (en)	2023-09-21
US20200138898A1 (en)	2020-05-07
KR20090037487A (ko)	2009-04-15
ZA200900550B (en)	2010-03-31
JP2013241428A (ja)	2013-12-05
CN103990111B (zh)	2016-08-31
US9827287B2 (en)	2017-11-28
CA2658949C (en)	2014-04-22
RU2009106673A (ru)	2010-09-10
US20090203620A1 (en)	2009-08-13
EP2722052B1 (en)	2019-03-20
PL2722052T3 (pl)	2019-08-30

Legal Events

Date	Code	Title	Description
2010-07-24	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100723
2010-07-24	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100723
2012-07-25	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120724
2012-10-19	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121018
2012-10-26	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121025
2012-11-22	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121121
2013-02-09	RD02	Notification of acceptance of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20130208
2013-02-28	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130208
2013-03-13	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130312
2013-03-14	RD04	Notification of resignation of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20130313
2013-07-12	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130711
2013-07-26	A911	Transfer to examiner for re-examination before appeal (zenchi)	Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130725
2013-08-29	TRDD	Decision of grant or rejection written
2013-09-04	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130903
2013-10-03	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130926
2013-10-04	R150	Certificate of patent or registration of utility model	Ref document number: 5378998 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150
2016-10-04	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2017-10-03	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2018-10-02	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2019-10-01	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2020-09-30	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2021-09-28	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2022-09-28	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2023-10-04	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
JP5378998B2 (ja)	2013-12-25	炎症性メディエーターの放出を減弱させるための方法及びそれにおいて有用なペプチド
US8563689B1 (en)	2013-10-22	Methods for regulating inflammatory mediators and peptides for useful therein
US8501911B2 (en)	2013-08-06	Methods of reducing inflammation and mucus hypersecretion
HK1191227A (en)	2014-07-25	Methods for attenuating release of inflammatory mediators and peptides useful therein
HK1125793B (en)	2014-09-12	Peptides for attenuating release of inflammatory mediators
HK1201190B (en)	2017-11-10	Methods for attenuating release of inflammatory mediators and peptides useful therein